Total Payments
$79,874
2024 Payments
$15,136
Companies
61
Transactions
269
Medicare Patients
5,242
Medicare Billing
$695,878
Payment Breakdown by Category
Consulting$39,194 (49.1%)
Other$27,381 (34.3%)
Travel$7,255 (9.1%)
Food & Beverage$5,855 (7.3%)
Education$188.92 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $39,194 | 29 | 49.1% |
| Honoraria | $21,421 | 14 | 26.8% |
| Travel and Lodging | $7,255 | 32 | 9.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,960 | 3 | 7.5% |
| Food and Beverage | $5,855 | 180 | 7.3% |
| Education | $188.92 | 10 | 0.2% |
| Unspecified | $0 | 1 | 0.0% |
Payments by Type
General
$79,874
268 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $11,934 | 15 | $0 (2024) |
| Incyte Corporation | $8,647 | 24 | $0 (2021) |
| Pharmacosmos Therapeutics Inc. | $7,280 | 10 | $0 (2024) |
| Kite Pharma, Inc. | $6,916 | 15 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $5,842 | 10 | $0 (2022) |
| Seattle Genetics, Inc. | $5,798 | 17 | $0 (2019) |
| Karyopharm Therapeutics Inc. | $4,968 | 7 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $3,278 | 3 | $0 (2024) |
| AMAG Pharmaceuticals, Inc. | $3,053 | 6 | $0 (2018) |
| GlaxoSmithKline, LLC. | $2,801 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,136 | 30 | Pharmacosmos Therapeutics Inc. ($7,280) |
| 2023 | $7,740 | 25 | Daiichi Sankyo Inc. ($4,464) |
| 2022 | $12,806 | 30 | JAZZ PHARMACEUTICALS INC. ($3,158) |
| 2021 | $8,991 | 44 | GlaxoSmithKline, LLC. ($2,750) |
| 2020 | $4,256 | 35 | Kite Pharma, Inc. ($1,350) |
| 2019 | $9,872 | 31 | Incyte Corporation ($4,689) |
| 2018 | $11,409 | 36 | Kite Pharma, Inc. ($3,861) |
| 2017 | $9,665 | 38 | Seattle Genetics, Inc. ($4,154) |
All Payment Transactions
269 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $116.90 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $20.31 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,410.00 | General |
| 10/23/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| 10/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.88 | General |
| Category: Oncology | ||||||
| 08/14/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,942.50 | General |
| 08/09/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Honoraria | Cash or cash equivalent | $5,294.00 | General |
| Category: HEMATOLOGY | ||||||
| 07/24/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| 07/24/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Travel and Lodging | Cash or cash equivalent | $41.00 | General |
| Category: HEMATOLOGY | ||||||
| 07/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.38 | General |
| Category: Diabetes | ||||||
| 06/29/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Travel and Lodging | In-kind items and services | $324.95 | General |
| Category: HEMATOLOGY | ||||||
| 06/29/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $76.23 | General |
| Category: HEMATOLOGY | ||||||
| 06/29/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $63.29 | General |
| Category: HEMATOLOGY | ||||||
| 06/29/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: HEMATOLOGY | ||||||
| 06/28/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Travel and Lodging | In-kind items and services | $605.94 | General |
| Category: HEMATOLOGY | ||||||
| 06/28/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Travel and Lodging | In-kind items and services | $477.66 | General |
| Category: HEMATOLOGY | ||||||
| 06/28/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Travel and Lodging | In-kind items and services | $233.54 | General |
| Category: HEMATOLOGY | ||||||
| 06/28/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $150.55 | General |
| Category: HEMATOLOGY | ||||||
| 05/30/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: Oncology | ||||||
| 05/29/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 04/26/2024 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $1,008.00 | General |
| 03/19/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 03/09/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $119.47 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 1,418 | 19,890 | $982,644 | $223,015 |
| 2022 | 26 | 1,217 | 25,971 | $679,623 | $157,659 |
| 2021 | 27 | 1,353 | 31,003 | $612,094 | $164,550 |
| 2020 | 25 | 1,254 | 27,146 | $521,441 | $150,655 |
Total Patients
5,242
Total Services
104,010
Medicare Billing
$695,878
Procedure Codes
105
All Medicare Procedures & Services
105 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 16 | 9,620 | $240,500 | $56,900 | 23.7% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 20 | 2,500 | $185,000 | $40,839 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 171 | 358 | $139,620 | $32,612 | 23.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 313 | 489 | $135,453 | $28,377 | 20.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 24 | 213 | $89,673 | $19,304 | 21.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 288 | 959 | $27,811 | $7,269 | 26.1% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 21 | 85 | $17,850 | $6,360 | 35.6% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 21 | 27 | $20,058 | $4,023 | 20.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $15,779 | $3,659 | 23.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 32 | 304 | $20,368 | $2,981 | 14.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 22 | $12,100 | $2,856 | 23.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 28 | 55 | $11,440 | $2,477 | 21.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 26 | 40 | $8,560 | $2,394 | 28.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 135 | 239 | $2,151 | $2,008 | 93.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 20 | $8,120 | $2,005 | 24.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 12 | $7,140 | $1,602 | 22.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 14 | 75 | $7,725 | $1,535 | 19.9% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 15 | 36 | $6,480 | $1,496 | 23.1% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 24 | 33 | $12,313 | $1,484 | 12.1% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 13 | 31 | $3,751 | $849.09 | 22.6% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 44 | 67 | $1,742 | $555.43 | 31.9% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 29 | 3,902 | $3,902 | $469.20 | 12.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 19 | 46 | $3,036 | $457.09 | 15.1% |
| 82565 | Blood creatinine level | Office | 2023 | 19 | 41 | $656.00 | $205.82 | 31.4% |
| 85045 | Red blood count, automated test | Office | 2023 | 44 | 49 | $588.00 | $191.59 | 32.6% |
About Dr. Mark Knapp, MD
Dr. Mark Knapp, MD is a Medical Oncology healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952359549.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Knapp, MD has received a total of $79,874 in payments from pharmaceutical and medical device companies, with $15,136 received in 2024. These payments were reported across 269 transactions from 61 companies. The most common payment nature is "Consulting Fee" ($39,194).
As a Medicare-enrolled provider, Knapp has provided services to 5,242 Medicare beneficiaries, totaling 104,010 services with total Medicare billing of $695,878. Data is available for 4 years (2020–2023), covering 105 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Columbus, OH
- Active Since 05/05/2006
- Last Updated 01/11/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1952359549
Products in Payments
- MONOFERRIC (Drug) $7,280
- Tavalisse (Drug) $5,842
- XPOVIO (Drug) $4,968
- ADCETRIS (Biological) $4,145
- VYXEOS (Drug) $3,150
- BRUKINSA (Drug) $3,117
- Yescarta (Drug) $3,055
- FERAHEME (Drug) $3,053
- BLENREP (Biological) $2,766
- Enhertu (Drug) $2,711
- TAZVERIK (Drug) $2,500
- Cabometyx (Drug) $2,355
- SUSTOL (Drug) $1,709
- Zydelig (Drug) $1,700
- AYVAKIT (Drug) $1,512
- Vonjo (Drug) $1,457
- Lenvima (Drug) $340.87
- OPDIVO (Biological) $160.48
- DARZALEX (Biological) $153.26
- SIR-Spheres Microspheres (Device) $142.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Columbus
Taral Patel, Md, MD
Medical Oncology — Payments: $826,872
Medical Oncology $826,872
Tarek Chidiac, Md, MD
Medical Oncology — Payments: $800,968
Medical Oncology $800,968
Robert Wesolowski, Md, MD
Medical Oncology — Payments: $281,784
Medical Oncology $281,784
Dr. Christian Rolfo, Md, MD
Medical Oncology — Payments: $235,782
Medical Oncology $235,782
Yuanquan Yang, M.d, M.D
Medical Oncology — Payments: $111,221
Medical Oncology $111,221
Dr. Timothy Burns, M.d. Ph.d, M.D. PH.D
Medical Oncology — Payments: $109,695
Medical Oncology $109,695